|
Title
|
|
|
|
Efficacy of the sentinox spray in reducing viral load in mild COVID-19 and its virucidal activity against other respiratory viruses : results of a randomized controlled trial and an in vitro study
| |
|
Author
|
|
|
|
| |
|
Institution/Organisation
|
|
|
|
STX Study Group
| |
|
Abstract
|
|
|
|
| Sentinox (STX) is an acid-oxidizing solution containing hypochlorous acid in spray whose virucidal activity against SARS-CoV-2 has been demonstrated. In this paper, results of a randomized controlled trial (RCT) on the efficacy of STX in reducing viral load in mild COVID-19 patients (NCT04909996) and a complementary in vitro study on its activity against different respiratory viruses are reported. In the RCT, 57 patients were randomized (1:1:1) to receive STX three (STX-3) or five (STX-5) times/day plus standard therapy or standard therapy only (controls). Compared with controls, the log10 load reduction in groups STX-3 and STX-5 was 1.02 (p = 0.14) and 0.18 (p = 0.80), respectively. These results were likely driven by outliers with extreme baseline viral loads. When considering subjects with baseline cycle threshold values of 20–30, STX-3 showed a significant (p = 0.016) 2.01 log10 reduction. The proportion of subjects that turned negative by the end of treatment (day 5) was significantly higher in the STX-3 group than in controls, suggesting a shorter virus clearance time. STX was safe and well-tolerated. In the in vitro study, ≥99.9% reduction in titers against common respiratory viruses was observed. STX is a safe device with large virucidal spectrum and may reduce viral loads in mild COVID-19 patients. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Viruses
| |
|
Publication
|
|
|
|
2022
| |
|
ISSN
|
|
|
|
1999-4915
| |
|
DOI
|
|
|
|
10.3390/V14051033
| |
|
Volume/pages
|
|
|
|
14
:5
(2022)
, p. 1-15
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|